TAK

Takeda Pharmaceutical Company Limited American Depositary Receipt (TAK) | Rumor.io

Takeda Pharmaceutical

TAK

Attention (50-day avg)0%

Attention rank (50-day avg)#2,236

Bullish sentiment (50-day avg)100%

Price to earnings ratio42.2

Market capitalization60.4B

Earnings per share-0.33

Dividend yield (TTM)3.67%

Revenue (annual)4.5T

Net income (annual)-152.1B

Social

What share of all stock conversation is about TAK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

May 25

The Takeda Pharmaceutical Company Limited (TAK) stock price is currently at $16.23.
A trade on TAK options has a 38% return on investment (ROI) with an entry price of $0.90 and an exit price of $1.24.
The trade was held for approximately 28 days.

Generated by AI

Sentiment

Of the messages about TAK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	71.58% -20.54
Bearish	—	—	0% 0	28.42% +20.54

Bullish· May 15

Takeda Pharmaceutical's agreement with Novavax in 2020 allowed for the transfer of technology to produce an adjuvant needed for the COVID vaccine, which can be manufactured in countries like South Korea and India with existing partners.
The purchase agreement between Sonafi and three large countries with significant populations and crowded cities creates a strong demand for the COVID vaccine, which Novavax's 95% effective vaccine is well-positioned to meet.
The logistics of manufacturing the vaccine in countries near Sonafi's facilities, using existing partners and minimizing imports and logistics costs, is a significant advantage for Novavax and Takeda Pharmaceutical.

Bearish· May 5

$TAK is in a buy zone as long as it stays above the trend line, indicating a potential area of support.
TAK's price action is dependent on its ability to stay above the trend line, which could be a point of weakness if it fails to hold.
The post does not provide any specific reasons or evidence for the bearish sentiment, but identifies a potential area of support as a buy zone.

Generated by AI

Topics

Of the messages about TAK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	13.54%	50.34%
Analysts	—	—	40.63%	13%
Controversies	—	—	5.21%	0.85%
Macro	—	—	40.63%	34.07%
Earnings	—	—	0%	1.26%
Technical Analysis	—	—	0%	0.49%

Announcements· Oct 22

Takeda Pharmaceutical Company Limited has discontinued its cell therapy efforts and will seek an external partner to leverage its cell therapy platform.
Takeda has entered into a license and collaboration agreement with Innovent Biologics for two late-stage oncology medicines, IBI363 and IBI343, for worldwide development and commercialization outside of Greater China.
Takeda has entered into a global strategic partnership with Innovent Biologics to bolster its oncology pipeline with next-generation investigational medicines for the treatment of solid tumors, with an upfront payment of $1.2B and potential milestones of up to $10.2B.

Macro· Jan 28

Takeda Pharmaceutical Company Limited may be affected by US tariffs on imported pharmaceuticals, weighing on Japan's sales growth.
The US market accounts for over half of Takeda's revenue, with unclear impact of imports on this figure.
Tariffs on pharmaceuticals could impact major Japanese drugmakers, including Takeda, Astellas, and Daiichi Sankyo.

Generated by AI

Community

Of the messages about TAK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	12.16%	12.49%
Newcomers	—	100%	87.84%	87.51%

Regulars· May 13

Takeda Pharmaceutical has agreed to pay $100 million upfront to AC Immune for an option on AC Immune's amyloid-targeting immunotherapy for Alzheimer's disease.
The deal gives Takeda the option to license the therapy globally, with AC Immune eligible for up to $2.1 billion in milestone payments.
Takeda will be responsible for conducting and funding further clinical development and global regulatory activities, as well as worldwide commercialization of the therapy.

Newcomers· Jun 18

New investors are looking into Takeda Pharmaceutical Company Limited as a single stock investment opportunity, specifically mentioning its Japanese value.
The company's pharmaceutical focus is of interest to newcomers, who see it as a potential investment opportunity.
Two newcomers are specifically considering Takeda Pharmaceuticals, along with KDDI, as their two Japanese stock investments.

Generated by AI

News

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

1d agoYahoo Finance

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

6d agoSeeking Alpha

Also Discussed

Investors talking about TAK also mention

#	Name	Attention
1	Denali Therapeutics Inc.DNLI	0%new
2	Sanofi ADRSNY	0%-0.01
3	Novartis AG Sponsored ADRNVS	0%-0.01
4	I-Mab Sponsored ADRIMAB	0%0
5	Ionis Pharmaceuticals, Inc.IONS	0%new
6	Jazz Pharmaceuticals plcJAZZ	0%0
7	Incyte Corp.INCY	0%new
8	Nkarta, Inc.NKTX	0%0
9	MYOV - Myovant Sciences Ltd.	——
10	BPMC - Blueprint Medicines Corporation	——

Takeda Pharmaceutical Company Limited American Depositary Receipt

Healthcare
Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Co Ltd ADR is a sponsored American depositary receipt representing shares of Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. Takeda develops, manufactures, markets, and out-licenses prescription medicines across major therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. Its portfolio is centered on specialty treatments and biologic medicines used in hospital, clinic, and outpatient settings, with commercial operations spanning Japan, the United States, Europe, and other international markets. The company also supports research and development, regulatory activities, and global manufacturing for small-molecule and biologic products. Takeda Pharmaceutical Co Ltd ADR provides U.S. investors with access to a diversified healthcare business focused on drug discovery, clinical development, and worldwide pharmaceutical commercialization.

Website

Location

1-1, Nihonbashi-Honcho 2-chome

Chuo, 103-8668

Japan

Social

What share of all stock conversation is about TAK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

May 25

The Takeda Pharmaceutical Company Limited (TAK) stock price is currently at $16.23.
A trade on TAK options has a 38% return on investment (ROI) with an entry price of $0.90 and an exit price of $1.24.
The trade was held for approximately 28 days.

Generated by AI

Sentiment

Of the messages about TAK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	71.58% -20.54
Bearish	—	—	0% 0	28.42% +20.54

Bullish· May 15

Takeda Pharmaceutical's agreement with Novavax in 2020 allowed for the transfer of technology to produce an adjuvant needed for the COVID vaccine, which can be manufactured in countries like South Korea and India with existing partners.
The purchase agreement between Sonafi and three large countries with significant populations and crowded cities creates a strong demand for the COVID vaccine, which Novavax's 95% effective vaccine is well-positioned to meet.
The logistics of manufacturing the vaccine in countries near Sonafi's facilities, using existing partners and minimizing imports and logistics costs, is a significant advantage for Novavax and Takeda Pharmaceutical.

Bearish· May 5

$TAK is in a buy zone as long as it stays above the trend line, indicating a potential area of support.
TAK's price action is dependent on its ability to stay above the trend line, which could be a point of weakness if it fails to hold.
The post does not provide any specific reasons or evidence for the bearish sentiment, but identifies a potential area of support as a buy zone.

Generated by AI

Topics

Of the messages about TAK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	13.54%	50.34%
Analysts	—	—	40.63%	13%
Controversies	—	—	5.21%	0.85%
Macro	—	—	40.63%	34.07%
Earnings	—	—	0%	1.26%
Technical Analysis	—	—	0%	0.49%

Announcements· Oct 22

Takeda Pharmaceutical Company Limited has discontinued its cell therapy efforts and will seek an external partner to leverage its cell therapy platform.
Takeda has entered into a license and collaboration agreement with Innovent Biologics for two late-stage oncology medicines, IBI363 and IBI343, for worldwide development and commercialization outside of Greater China.
Takeda has entered into a global strategic partnership with Innovent Biologics to bolster its oncology pipeline with next-generation investigational medicines for the treatment of solid tumors, with an upfront payment of $1.2B and potential milestones of up to $10.2B.

Macro· Jan 28

Takeda Pharmaceutical Company Limited may be affected by US tariffs on imported pharmaceuticals, weighing on Japan's sales growth.
The US market accounts for over half of Takeda's revenue, with unclear impact of imports on this figure.
Tariffs on pharmaceuticals could impact major Japanese drugmakers, including Takeda, Astellas, and Daiichi Sankyo.

Generated by AI

Community

Of the messages about TAK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	12.16%	12.49%
Newcomers	—	100%	87.84%	87.51%

Regulars· May 13

Takeda Pharmaceutical has agreed to pay $100 million upfront to AC Immune for an option on AC Immune's amyloid-targeting immunotherapy for Alzheimer's disease.
The deal gives Takeda the option to license the therapy globally, with AC Immune eligible for up to $2.1 billion in milestone payments.
Takeda will be responsible for conducting and funding further clinical development and global regulatory activities, as well as worldwide commercialization of the therapy.

Newcomers· Jun 18

New investors are looking into Takeda Pharmaceutical Company Limited as a single stock investment opportunity, specifically mentioning its Japanese value.
The company's pharmaceutical focus is of interest to newcomers, who see it as a potential investment opportunity.
Two newcomers are specifically considering Takeda Pharmaceuticals, along with KDDI, as their two Japanese stock investments.

Generated by AI

Takeda Pharmaceutical

Social

May 25

Bullish· May 15

Bearish· May 5

Announcements· Oct 22

Macro· Jan 28

Regulars· May 13

Newcomers· Jun 18

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

Roche proposes former Takeda CEO for board seat

Dr. Reddy’s to Roll Out Takeda’s Dengue Jab in India Next Year

Dr Reddy’s to distribute Takeda’s dengue vaccine in India

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Also Discussed

Takeda Pharmaceutical Company Limited American Depositary Receipt

Company Information

Location

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

Roche proposes former Takeda CEO for board seat

Dr. Reddy’s to Roll Out Takeda’s Dengue Jab in India Next Year

Dr Reddy’s to distribute Takeda’s dengue vaccine in India

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Also Discussed

Social

May 25

Bullish· May 15

Bearish· May 5

Announcements· Oct 22

Macro· Jan 28

Regulars· May 13

Newcomers· Jun 18